Physician profile
Wayne Bailey
NPI 1467698712
$17,905.22
in general payments reported to CMS, 2019-2025
36 companies · $4,816 in 2025
The $4,816 reported for 2025 was more than what 85% of Rheumatology providers received nationally (typical 2025 total: $894).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $15.94 · 2021: $2,006 · 2022: $2,438 · 2023: $4,444 · 2024: $4,185 · 2025: $4,816.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $13K · Education: $474.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $12,971.29 |
| Education | $474.20 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Biotech, INC. | $3,652.72 | 2021-2025 | Tremfya, Simponi Aria, Stelara |
| Amgen INC. | $2,595.49 | 2021-2025 | Evenity, Tavneos, Enbrel |
| Ucb, INC. | $1,721.69 | 2021-2025 | Cimzia, Bimzelx |
| Mallinckrodt Hospital Products INC. | $1,429.27 | 2021-2025 | Acthar |
| Novartis Pharmaceuticals Corporation | $1,258.73 | 2021-2025 | |
| Ani Pharmaceuticals, INC. | $1,001.43 | 2022-2025 | Purified Cortrophin Gel, Sovuna |
| Abbvie INC. | $919.23 | 2024-2025 | |
| Radius Health, INC. | $814.29 | 2021-2025 | Tymlos |
| Glaxosmithkline, LLC. | $733.55 | 2021-2025 | Benlysta, Nucala |
| Pfizer INC. | $460.60 | 2021-2023 | |
| E.R. Squibb & Sons, L.L.C. | $441.39 | 2021-2025 | Orencia |
| Lilly USA, LLC | $381.87 | 2021-2024 | Taltz |
| Aurinia Pharma U.S., INC. | $321.76 | 2021-2025 | Lupkynis |
| Alexion Pharmaceuticals, INC. | $315.71 | 2022-2025 | Strensiq |
| Genentech USA, INC. | $292.37 | 2021-2025 | Actemra, Rituxan |
Show all 36 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Fresenius Kabi USA, LLC | $244.82 | 2023-2024 | Idacio |
| Horizon Therapeutics Plc | $243.32 | 2019-2023 | Krystexxa |
| Sandoz INC. | $186.50 | 2023-2025 | Hyrimoz, Jubbonti |
| Astrazeneca Pharmaceuticals Lp | $164.02 | 2021-2025 | Saphnelo |
| Kyowa Kirin, INC. | $97.63 | 2023-2025 | Crysvita |
| Fidia Pharma USA INC. | $96.59 | 2022-2025 | Hymovis |
| Depuy Synthes Sales INC. | $82.45 | 2024 | Orthovisc, Monovisc, Peak |
| Tersera Therapeutics LLC | $81.15 | 2025 | Quzyttir |
| Biocon Biologics INC | $50.94 | 2023-2024 | Hulio |
| Boehringer Ingelheim Pharmaceuticals, INC. | $45.84 | 2024-2025 | Jascayd, Ofev |
| Ultragenyx Pharmaceutical INC. | $38.94 | 2021-2023 | |
| Janssen Pharmaceuticals, INC | $33.90 | 2025 | Tremfya |
| Mylan Institutional INC. | $29.53 | 2023 | Hulio |
| Si-Bone, INC. | $26.92 | 2021 | |
| Genzyme Corporation | $24.98 | 2024 | |
| Boston Scientific Corporation | $24.54 | 2024 | |
| Organon LLC | $23.42 | 2025 | Renflexis, Hadlima |
| Cumberland Pharmaceuticals, INC. | $22.50 | 2022 | |
| Actelion Pharmaceuticals US, INC. | $21.69 | 2021 | |
| Alvogen INC | $14.40 | 2025 | Teriparatide |
| Hikma Pharmaceuticals USA | $11.04 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Wayne Bailey listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.